TTC13 Inhibitors
TTC13 inhibitors are a class of chemical compounds designed to selectively inhibit the TTC13 protein, a member of the tetratricopeptide repeat (TPR) domain-containing protein family. The TTC13 protein is involved in various cellular processes, particularly through its role in mediating protein-protein interactions. The TPR domains within TTC13 function as structural motifs that facilitate the assembly of multi-protein complexes, critical for regulating diverse intracellular signaling pathways and molecular interactions. TTC13 inhibitors work by binding to specific regions of the protein, such as its TPR domains, to prevent TTC13 from interacting with its natural protein partners. This disruption can alter cellular signaling pathways and the dynamics of protein complex formation, leading to a deeper understanding of TTC13's functional role within the cell.
Chemically, TTC13 inhibitors are often small molecules with distinct structural features that enable high specificity for the TTC13 protein. These compounds typically include a combination of hydrophobic groups, hydrogen bond donors, and acceptors, which allow for precise binding to TTC13's active or binding sites. In the development of TTC13 inhibitors, emphasis is placed on achieving a high degree of selectivity to avoid interference with other TPR-containing proteins, which share similar structural features but perform different cellular functions. By studying the interaction of these inhibitors with TTC13, researchers can explore the conformational changes and functional impacts on protein complexes. This research provides valuable insights into how TTC13 operates within broader cellular networks and contributes to regulatory processes, making TTC13 inhibitors a useful tool in understanding the molecular mechanics of TPR domain proteins.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
An inhibitor of ADP-ribosylation factor (ARF), Brefeldin A disrupts Golgi structure and function, potentially affecting the post-translational modification processes such as glycylation which TTLL13 is involved in, leading to its functional inhibition. | ||||||
Colchicine | 64-86-8 | sc-203005 sc-203005A sc-203005B sc-203005C sc-203005D sc-203005E | 1 g 5 g 50 g 100 g 500 g 1 kg | $100.00 $321.00 $2289.00 $4484.00 $18207.00 $34749.00 | 3 | |
By binding to tubulin and inhibiting its polymerization, Colchicine can interfere with microtubule formation and subsequently inhibit the microtubule-dependent enzyme TTLL13 from performing its glycylation function on tubulin. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
An activator of adenylate cyclase, Forskolin raises intracellular cAMP levels which may indirectly inhibit TTLL13 by promoting PKA activity that could phosphorylate substrates or regulatory proteins that suppress TTLL13's enzyme activity. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $291.00 $530.00 $1800.00 | 78 | |
As a potent inhibitor of protein phosphatases PP1 and PP2A, Okadaic Acid can lead to hyperphosphorylation of cellular proteins, which may indirectly inhibit TTLL13 by disrupting regulatory pathways that control its enzymatic activity. | ||||||
Taxol | 33069-62-4 | sc-201439D sc-201439 sc-201439A sc-201439E sc-201439B sc-201439C | 1 mg 5 mg 25 mg 100 mg 250 mg 1 g | $41.00 $74.00 $221.00 $247.00 $738.00 $1220.00 | 39 | |
By stabilizing microtubules and preventing their disassembly, Taxol may reduce the availability of tubulin substrates for TTLL13, indirectly inhibiting its glycylation activity. | ||||||
Vinblastine | 865-21-4 | sc-491749 sc-491749A sc-491749B sc-491749C sc-491749D | 10 mg 50 mg 100 mg 500 mg 1 g | $102.00 $235.00 $459.00 $1749.00 $2958.00 | 4 | |
Vinblastine binds to tubulin and inhibits microtubule assembly, which can lead to a decrease in substrate availability for TTLL13 and an indirect inhibition of its glycylation function. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $59.00 $85.00 $143.00 $247.00 | 38 | |
A microtubule-depolymerizing agent, Nocodazole can prevent the formation of microtubules, thus indirectly inhibiting TTLL13 by reducing the substrate (tubulin) necessary for its activity. | ||||||
Podophyllotoxin | 518-28-5 | sc-204853 | 100 mg | $84.00 | 1 | |
By inhibiting tubulin polymerization and microtubule assembly, Podophyllotoxin can indirectly inhibit TTLL13's glycylation activity by decreasing the availability of its tubulin substrates. | ||||||
β-Estradiol | 50-28-2 | sc-204431 sc-204431A | 500 mg 5 g | $63.00 $182.00 | 8 | |
Estradiol can modulate various signaling pathways in the cell, including those involved in cytoskeletal regulation, potentially leading to indirect inhibition of TTLL13 by altering the dynamics of tubulin modification. | ||||||
Methotrexate | 59-05-2 | sc-3507 sc-3507A | 100 mg 500 mg | $94.00 $213.00 | 33 | |
Methotrexate can lead to depletion of nucleotide pools and may indirectly affect the post-translational modification of proteins, including the inhibition of TTLL13's activity. | ||||||